Albany, NY -- (SBWIRE) -- 10/23/2018 -- DelveInsight has announced the addition of the "Neuroblastoma(NB) Market Insights, Epidemiology and Market Forecast-2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Neuroblastoma for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice & Neuroblastoma forecasted epidemiology from 2018 to 2027, segmented by seven major markets.
Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It is derived from two words i.e. neuro means nerves and blastoma refers to a tumour affecting the immature or developing cells. It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present. Neuroblastoma is most common in very young children, but it is rare in children over the age of 10 years. Approximately 1% to 2% of patients with neuroblastoma inherit an increased risk of developing neuroblastoma from their parents.

Request for sample pages:https://www.delveinsight.com/dev-sample.php?form_name=Neuroblastoma---Market-Insight,-Epidemiology-and-Market-Forecast---2027

The total Neuroblastoma incident cases in US were found to be ~600 in 2016. Among the European countries, France has the highest incident population of neuroblastoma with ~156 cases followed by the United Kingdom which has an incident population of ~ 146 in 2016. Spain has the lowest incident population. As per the country analysis, the US has the highest number of cases, followed by Japan and other European countries. The patients are also classified based on the risk groups i.e. low risk, intermediate risk and high-risk NB incident cases. The larger number of patients were observed in the High-risk groups as compared to low and intermediate groups.

The therapeutic market of Neuroblastoma in seven major markets is growing at a Compound Annual Growth Rate (CAGR) of 6.3% for the forecast period 2016-2027. The United States accounts for 62% of the total sales in 2016 and will occupy 53% of the total market by 2027. Unituxin is the 7MM market leader, which accounted for 71% of the market share in 2016 and similar pattern observed in the US, where Unituxin has the largest market share in 2016. The withdrawal of its application from Europe in 2017 will largely impact its market in the European countries and will also restrict its growth in the forecast period. The drug will achieve its peak sales of $XX million by 2020. The launch of Qarziba in US, EU and Japan will have a great impact on the overall market. The drug will fill the void created by Unituxin in EU and expected to capture the market easily. The drug is expected to cross the sales of existing therapy Unituxin due to its higher uptake in the markets. We have expected the launch of Qarziba in Japan and US by 2019.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Report Scope

The report covers a descriptive overview of the Neuroblastoma, explaining its causes and the currently available therapies. The report provides an insight into the epidemiology of the disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. The report is a comprehensive account of both the current and emerging therapies, assessing the impact of new therapies on the current treatment landscape. The report also reviews the detailed global historical and forecasted Neuroblastoma market including the drug outreach in 7 MM. The report helps in developing business strategies by understanding trends shaping and driving the global Neuroblastoma market.